Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7555346 | 0.92 | DRD4 (0.45) | DRD4DRD2ALDH1A1PKMKCNA5 | |
| SCHEMBL7550921 | 0.88 | DRD2 (0.46) | DRD4DRD2ALDH1A1OPRM1DRD3 | |
| SCHEMBL7548092 | 0.82 | DRD2 (0.47) | DRD4DRD2ALDH1A1MTNR1AMTNR1B | |
| SCHEMBL7552597 | 0.80 | DRD2 (0.46) | DRD4DRD2ALDH1A1MTNR1AMTNR1B | |
| SCHEMBL7552605 | 0.78 | DRD2 (0.40) | DRD4DRD2ALDH1A1OPRM1DRD3 | |
| SCHEMBL7549185 | 0.75 | NISCH (0.53) | DRD2SLC6A2SLC6A4MTNR1AMTNR1B | |
| SCHEMBL7551253 | 0.74 | DRD2 (0.41) | DRD2KCNA5SLC6A2SLC6A4MTNR1A | |
| SCHEMBL7554011 | 0.73 | NISCH (0.45) | DRD2ALDH1A1SLC6A2SLC6A4MTNR1A | |
| SCHEMBL7546358 | 0.72 | PBRM1 (0.46) | DRD2KCNA5SLC6A2SLC6A4MTNR1A | |
| SCHEMBL7547015 | 0.70 | DRD2 (0.41) | DRD2ALDH1A1KCNA5SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020132812-A1 | Oral hypoglycaemic agents | NOVO NORDISK A/S (DK) | 2002-09-19 | — | — | US | disclosed |
| WO-2002038559-A1 | 1,3-DIAZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS ORAL HYPOGLYCAEMIC AGENTS | NOVO NORDISK A/S (DK) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132812-A1 | Oral hypoglycaemic agents | SLC5A2, GPR119, SLC5A1 | DRD4 2942/4885DRD2 3857/4885ALDH1A1 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.